A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis

Antibodies against cyclic citrullinated peptide (CCP) and rheumatoid factors (RFs) have been demonstrated to predate the onset of rheumatoid arthritis (RA) by years. A nested case–control study was performed within the Northern Sweden Health and Disease study cohort to analyse the presence of shared...

Full description

Bibliographic Details
Published in:Arthritis Research & Therapy
Main Authors: Berglin, Ewa, Padyukov, Leonid, Sundin, Ulf, Hallmans, Göran, Stenlund, Hans, van Venrooij, Walther J, Klareskog, Lars, Dahlqvist, Solbritt Rantapää
Format: Text
Language:English
Published: BioMed Central 2004
Subjects:
Online Access:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC464874
http://www.ncbi.nlm.nih.gov/pubmed/15225365
https://doi.org/10.1186/ar1187
id ftpubmed:oai:pubmedcentral.nih.gov:464874
record_format openpolar
spelling ftpubmed:oai:pubmedcentral.nih.gov:464874 2023-05-15T17:45:08+02:00 A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis Berglin, Ewa Padyukov, Leonid Sundin, Ulf Hallmans, Göran Stenlund, Hans van Venrooij, Walther J Klareskog, Lars Dahlqvist, Solbritt Rantapää 2004 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC464874 http://www.ncbi.nlm.nih.gov/pubmed/15225365 https://doi.org/10.1186/ar1187 en eng BioMed Central http://www.ncbi.nlm.nih.gov/pmc/articles/PMC464874 http://www.ncbi.nlm.nih.gov/pubmed/15225365 http://dx.doi.org/10.1186/ar1187 Copyright © 2004 Berglin et al.; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL. Research Article Text 2004 ftpubmed https://doi.org/10.1186/ar1187 2013-08-30T01:02:31Z Antibodies against cyclic citrullinated peptide (CCP) and rheumatoid factors (RFs) have been demonstrated to predate the onset of rheumatoid arthritis (RA) by years. A nested case–control study was performed within the Northern Sweden Health and Disease study cohort to analyse the presence of shared epitope (SE) genes, defined as HLA-DRB1*0404 or DRB1*0401, and of anti-CCP antibodies and RFs in individuals who subsequently developed RA. Patients with RA were identified from among blood donors whose samples had been collected years before the onset of symptoms. Controls matched for age, sex, and date of sampling were selected randomly from the same cohort. The SE genes were identified by polymerase chain reaction sequence-specific primers. Anti-CCP2 antibodies and RFs were determined using enzyme immunoassays. Fifty-nine individuals with RA were identified as blood donors, with a median antedating time of 2.0 years (interquartile range 0.9–3.9 years) before presenting with symptoms of RA. The sensitivity for SE as a diagnostic indicator for RA was 60% and the specificity was 64%. The corresponding figures for anti-CCP antibodies were 37% and 98%, and for RFs, 17–42% and 94%, respectively. In a logistic regression analysis, SE (odds ratio [OR] = 2.35), anti-CCP antibodies (OR = 15.9), and IgA-RF (OR = 6.8) significantly predicted RA. In a combination model analysis, anti-CCP antibodies combined with SE had the highest OR (66.8, 95% confidence interval 8.3–539.4) in predicting RA, compared with anti-CCP antibodies without SE (OR = 25.01, 95% confidence interval 2.8–222.2) or SE without anti-CCP antibodies (OR = 1.9, 95% confidence interval 0.9–4.2). This study showed that the presence of anti-CCP antibodies together with SE gene carriage is associated with a very high relative risk for future development of RA. Text Northern Sweden PubMed Central (PMC) Arthritis Research & Therapy 6 4 R303
institution Open Polar
collection PubMed Central (PMC)
op_collection_id ftpubmed
language English
topic Research Article
spellingShingle Research Article
Berglin, Ewa
Padyukov, Leonid
Sundin, Ulf
Hallmans, Göran
Stenlund, Hans
van Venrooij, Walther J
Klareskog, Lars
Dahlqvist, Solbritt Rantapää
A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis
topic_facet Research Article
description Antibodies against cyclic citrullinated peptide (CCP) and rheumatoid factors (RFs) have been demonstrated to predate the onset of rheumatoid arthritis (RA) by years. A nested case–control study was performed within the Northern Sweden Health and Disease study cohort to analyse the presence of shared epitope (SE) genes, defined as HLA-DRB1*0404 or DRB1*0401, and of anti-CCP antibodies and RFs in individuals who subsequently developed RA. Patients with RA were identified from among blood donors whose samples had been collected years before the onset of symptoms. Controls matched for age, sex, and date of sampling were selected randomly from the same cohort. The SE genes were identified by polymerase chain reaction sequence-specific primers. Anti-CCP2 antibodies and RFs were determined using enzyme immunoassays. Fifty-nine individuals with RA were identified as blood donors, with a median antedating time of 2.0 years (interquartile range 0.9–3.9 years) before presenting with symptoms of RA. The sensitivity for SE as a diagnostic indicator for RA was 60% and the specificity was 64%. The corresponding figures for anti-CCP antibodies were 37% and 98%, and for RFs, 17–42% and 94%, respectively. In a logistic regression analysis, SE (odds ratio [OR] = 2.35), anti-CCP antibodies (OR = 15.9), and IgA-RF (OR = 6.8) significantly predicted RA. In a combination model analysis, anti-CCP antibodies combined with SE had the highest OR (66.8, 95% confidence interval 8.3–539.4) in predicting RA, compared with anti-CCP antibodies without SE (OR = 25.01, 95% confidence interval 2.8–222.2) or SE without anti-CCP antibodies (OR = 1.9, 95% confidence interval 0.9–4.2). This study showed that the presence of anti-CCP antibodies together with SE gene carriage is associated with a very high relative risk for future development of RA.
format Text
author Berglin, Ewa
Padyukov, Leonid
Sundin, Ulf
Hallmans, Göran
Stenlund, Hans
van Venrooij, Walther J
Klareskog, Lars
Dahlqvist, Solbritt Rantapää
author_facet Berglin, Ewa
Padyukov, Leonid
Sundin, Ulf
Hallmans, Göran
Stenlund, Hans
van Venrooij, Walther J
Klareskog, Lars
Dahlqvist, Solbritt Rantapää
author_sort Berglin, Ewa
title A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis
title_short A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis
title_full A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis
title_fullStr A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis
title_full_unstemmed A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis
title_sort combination of autoantibodies to cyclic citrullinated peptide (ccp) and hla-drb1 locus antigens is strongly associated with future onset of rheumatoid arthritis
publisher BioMed Central
publishDate 2004
url http://www.ncbi.nlm.nih.gov/pmc/articles/PMC464874
http://www.ncbi.nlm.nih.gov/pubmed/15225365
https://doi.org/10.1186/ar1187
genre Northern Sweden
genre_facet Northern Sweden
op_relation http://www.ncbi.nlm.nih.gov/pmc/articles/PMC464874
http://www.ncbi.nlm.nih.gov/pubmed/15225365
http://dx.doi.org/10.1186/ar1187
op_rights Copyright © 2004 Berglin et al.; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.
op_doi https://doi.org/10.1186/ar1187
container_title Arthritis Research & Therapy
container_volume 6
container_issue 4
container_start_page R303
_version_ 1766147896293457920